Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin
December 15, 2020 08:30 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham
December 07, 2020 08:15 ET
|
Silo Pharma, Inc.
NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets
December 04, 2020 16:52 ET
|
Silo Pharma, Inc.
NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco
November 16, 2020 09:40 ET
|
Silo Pharma, Inc.
NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D....
Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications
November 12, 2020 07:07 ET
|
Silo Pharma, Inc.
Each Provisional Patent Application Relates to Psilocybin NEW YORK , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on...
Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University
November 09, 2020 07:15 ET
|
Silo Pharma, Inc.
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has...
Silo Pharma, Inc. (SILO) Announces Successful Uplisting To the OTCQB Venture Market
October 14, 2020 10:06 ET
|
Silo Pharma, Inc.
To Begin Trading on the OTCQB Venture Market Under the Symbol “SILO” Today NEW YORK , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage...
Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides
October 13, 2020 08:45 ET
|
Uppercut Brands, Inc.
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, announced that it...
Silo Pharma, Inc. Expands Board with Appointment of Dr. Kevin Muñoz MD; Announces Application to Uplist to OTCQB Market
October 06, 2020 09:55 ET
|
Uppercut Brands, Inc.
NEW YORK , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO), which recently announced its transformation to a developmental stage biopharmaceutical company focused on the use of...
Uppercut Brands, Inc. Changes Name to Silo Pharma, Inc.; reflecting Company’s Emerging Focusing on the Development and Commercialization of Psychedelic/Psilocybin-based Drug Therapies
September 28, 2020 09:14 ET
|
Uppercut Brands, Inc.
Early Entrant, Addressing Massive Market Opportunity for Psychedelic Drug Therapies for a Wide-Range of Conditions, Including PTSD and Parkinson’s Disease; Company to Trade Under New Symbol SILO ...